Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 10/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 8/20 | 0.43 |
| ▸ | CRHR1 | P34998 | 5/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5415195 | 0.84 | CRHR1 (0.47) | CRHR1 | |
| SCHEMBL5419442 | 0.80 | CRHR1 (0.63) | CRHR1 | |
| SCHEMBL5533131 | 0.77 | CRHR1 (0.51) | CRHR1 | |
| SCHEMBL5415016 | 0.77 | CRHR1 (0.51) | CRHR1 | |
| SCHEMBL5412326 | 0.77 | CRHR1 (0.46) | CRHR1 | |
| SCHEMBL5417114 | 0.76 | CRHR1 (0.50) | CRHR1 | |
| SCHEMBL5414792 | 0.74 | CRHR1 (0.64) | CRHR1 | |
| SCHEMBL5414334 | 0.72 | CRHR1 (0.46) | CRHR1 | |
| SCHEMBL5417698 | 0.71 | CNR1 (0.51) | CRHR1 | |
| SCHEMBL5412305 | 0.70 | CRHR1 (0.48) | CRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070225287-A1 | Substituted Arylpyrazines | YOON TAEYOUNG | 2007-09-27 | — | — | US | disclosed |
| US-7202250-B2 | Substituted arylpyrazines | NEUROGEN CORPORATION (US) | 2007-04-10 | — | — | US | disclosed |
| US-6995161-B2 | Substituted arylpyrazines | NEUROGEN CORPORATION (US) | 2006-02-07 | — | — | US | disclosed |
| US-20050215559-A1 | Substituted arylpyrazines | NEUROGEN CORPORATION | 2005-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070225287-A1 | Substituted Arylpyrazines | CRHR1, CRHR2, CRH | SLC6A4 193/4885SLC6A3 222/4885SLC6A2 157/4885 |
| US-20050215559-A1 | Substituted arylpyrazines | CRHR1, CRHR2, CRH | SLC6A4 193/4885SLC6A3 222/4885SLC6A2 157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.